Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients

Heart and Vessels

Volumn 30, Issue 5, 2015, Pages 696-701

  Fujiwara, Takayuki ^a   Yoshida, Masashi ^a   Nakamura, Tomohiro ^a   Sakakura, Kenichi ^a   Wada, Hiroshi ^a   Arao, Kenshiro ^a   Katayama, Takuji ^a   Funayama, Hiroshi ^a   Sugawara, Yoshitaka ^a   Mitsuhashi, Takeshi ^a   Kakei, Masafumi ^a   Momomura, Shin ichi ^a   Ako, Junya ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Acute myocardial infarction; Diabetes mellitus; Diastolic function; Dipeptidyl peptidase 4 inhibitor

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; SITAGLIPTIN; VILDAGLIPTIN;

ACUTE HEART INFARCTION; ADULT; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; E-A RATIO; E-E RATIO; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICULAR DIASTOLIC FUNCTION; HEART LEFT VENTRICULAR SYSTOLIC FUNCTION; HUMAN; LEFT VENTRICLE DIASTOLIC DIAMETER; LEFT VENTRICLE SYSTOLIC DIAMETER; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TOTAL QUALITY MANAGEMENT; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; COMPLICATION; DIASTOLE; DRUG EFFECTS; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; MIDDLE AGED; MYOCARDIAL INFARCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; DIABETES MELLITUS, TYPE 2; DIASTOLE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84941419937     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-014-0509-4     Document Type: Article

References (15)

1. Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)–role in the inactivation of regulatory peptides. Regul Pept 85(1):9–24
2. Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW, Gorrell MD (2010) The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 277(5):1126–1144
3. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696–1705
4. Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, David R, Fischer R, Krieg L, Hirsch E, Huber B, Nathan P, Israel L, Imhof A, Herbach N, Assmann G, Wanke R, Mueller-Hoecker J, Steinbeck G, Franz WM (2009) Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4(4):313–323
5. Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59(4):1063–1073
6. Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K, Murohara T (2012) Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 126(15):1838–1851
7. Connelly KA, Zhang Y, Advani A, Advani SL, Thai K, Yuen DA, Gilbert RE (2013) DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther 31(5):259–267
8. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326
9. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335
10. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117(18):2340–2350
11. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4):975–983
12. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS (2003) Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 362(9385):697–703
13. Takahashi M (2010) Role of the SDF-1/CXCR4 system in myocardial infarction. Circ J 74(3):418–423
14. Segal MS, Shah R, Afzal A, Perrault CM, Chang K, Schuler A, Beem E, Shaw LC, Li Calzi S, Harrison JK, Tran-Son-Tay R, Grant MB (2006) Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 55(1):102–109
15. Zhang D, Huang W, Dai B, Zhao T, Ashraf A, Millard RW, Ashraf M, Wang Y (2010) Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts. Am J Physiol Heart Circ Physiol 299(5):H1339–H1347